<div id="readability-page-1"><div><p>Over the last 7 days, the United States market has remained flat, although it is up 29% over the past year with earnings forecast to grow by 16% annually. In this context of steady growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive market conditions.</p><h3>Top 10 High Growth Tech Companies In The United States</h3><div><table><tbody><tr><th>Name</th><th>Revenue Growth</th><th>Earnings Growth</th><th>Growth Rating</th></tr><tr><td>Marker Therapeutics</td><td>61.33%</td><td>65.71%</td><td>★★★★★★</td></tr><tr><td>Palantir Technologies</td><td>27.37%</td><td>30.93%</td><td>★★★★★★</td></tr><tr><td>Reddit</td><td>21.66%</td><td>27.62%</td><td>★★★★★★</td></tr><tr><td>Fabrinet</td><td>20.36%</td><td>22.11%</td><td>★★★★★★</td></tr><tr><td>Sandisk</td><td>35.48%</td><td>49.66%</td><td>★★★★★★</td></tr><tr><td>Tenaya Therapeutics</td><td>58.52%</td><td>60.10%</td><td>★★★★★☆</td></tr><tr><td>Zscaler</td><td>15.95%</td><td>49.84%</td><td>★★★★★☆</td></tr><tr><td>Circle Internet Group</td><td>20.27%</td><td>46.38%</td><td>★★★★★☆</td></tr><tr><td>Duos Technologies Group</td><td>36.60%</td><td>141.19%</td><td>★★★★★☆</td></tr><tr><td>KVH Industries</td><td>25.44%</td><td>135.75%</td><td>★★★★★☆</td></tr></tbody></table></div><p>Click here to see the full list of 66 stocks from our US High Growth Tech and AI Stocks screener.</p><p>Here's a peek at a few of the choices from the screener.</p><h2>AvePoint (AVPT)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> AvePoint, Inc. offers a cloud-native data management software platform across various regions including North America, Europe, the Middle East, Africa, and the Asia Pacific with a market capitalization of approximately $2.16 billion.</p><p><strong>Operations:</strong> The company generates revenue primarily from its software and programming segment, totaling $419.50 million.</p><p>AvePoint's recent trajectory illustrates a robust adaptation to the evolving tech landscape, underscored by a significant turnaround in financial performance. In 2025, the company reported a revenue increase to $419.5 million from $330.48 million the previous year, alongside an impressive swing to a net income of $34.8 million from a net loss of $29.09 million, reflecting an earnings growth of 32.07% per year. These figures are complemented by AvePoint's strategic enhancements in AI governance capabilities across multiple cloud platforms such as Microsoft 365 and Google Cloud, addressing critical multicloud compliance and data security challenges faced by enterprises today. This strategic pivot not only boosts their service offerings but also positions them well within the high-growth sectors of cloud governance and data management, tapping into escalating demands for integrated AI solutions that ensure both operational efficiency and stringent security protocols.</p><ul><li>Delve into the full analysis health report here for a deeper understanding of AvePoint.</li><li>Gain insights into AvePoint's past trends and performance with our Past report.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/757b1f34-6adb-40bf-9718-ec65d6ce15ee/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/757b1f34-6adb-40bf-9718-ec65d6ce15ee/chart/earnings-and-revenue-growth"/><figcaption>AVPT Earnings and Revenue Growth as at Apr 2026</figcaption></figure><h2>Krystal Biotech (KRYS)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for diseases with high unmet medical needs in the United States, with a market cap of $7.92 billion.</p><p><strong>Operations:</strong> Krystal Biotech generates revenue primarily from its genetic medicines segment, which amounted to $389.13 million. The company operates within the biotechnology sector, focusing on addressing diseases with significant unmet needs in the U.S.</p><p>Krystal Biotech stands out in the biotechnology landscape, showcasing a remarkable earnings growth of 129.7% over the past year, significantly outpacing the industry's average of 50.1%. This growth is underpinned by robust revenue and earnings forecasts, with expected annual increases of 19.8% and 22%, respectively, which eclipse broader market projections. The firm's commitment to innovation is evident in its recent FDA RMAT designation for KB707, aimed at treating advanced NSCLC—a testament to its potential in addressing critical unmet medical needs through advanced gene therapies. This strategic focus not only highlights Krystal’s role in pioneering new treatments but also positions it favorably within a competitive sector poised for rapid expansion.</p><ul><li>Navigate through the intricacies of Krystal Biotech with our comprehensive health report here.</li><li>Review our historical performance report to gain insights into Krystal Biotech's's past performance.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth"/><figcaption>KRYS Earnings and Revenue Growth as at Apr 2026</figcaption></figure><h2>Q2 Holdings (QTWO)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> Q2 Holdings, Inc. offers digital solutions tailored for financial institutions, FinTechs, and alternative finance companies across the United States, with a market capitalization of $3.03 billion.</p><p><strong>Operations:</strong> Q2 Holdings generates revenue primarily through the sale, implementation, and support of its digital solutions, amounting to $794.81 million. The company caters to financial institutions and FinTechs in the U.S., focusing on providing technology-driven services.</p><p>Q2 Holdings is distinguishing itself in the tech sector with a strong focus on AI-driven solutions for financial services, evidenced by its recent unveiling of User Activity Monitoring and Restricted Entitlements Mode to enhance fraud protection. These innovations are part of Q2's broader strategy to integrate AI seamlessly within digital banking operations, reflecting a significant shift towards more dynamic, real-time fraud mitigation techniques. Financially, Q2 has demonstrated robust growth with a 34.5% annual increase in earnings and an impressive 9.6% rise in revenue year-over-year. This performance is underpinned by strategic initiatives like Second Quarter Code, which accelerates development cycles within financial institutions by leveraging generative AI, thereby enhancing the platform's utility and attractiveness in a competitive market.</p><ul><li>Dive into the specifics of Q2 Holdings here with our thorough health report.</li><li>Assess Q2 Holdings' past performance with our detailed historical performance reports.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7cb340fc-3efd-4236-8da6-fed86e0ccf86/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7cb340fc-3efd-4236-8da6-fed86e0ccf86/chart/earnings-and-revenue-growth"/><figcaption>QTWO Earnings and Revenue Growth as at Apr 2026</figcaption></figure><h2>Make It Happen</h2><ul><li>Investigate our full lineup of 66 US High Growth Tech and AI Stocks right here.</li><li>Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.</li><li>Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.</li></ul><h2>Ready To Venture Into Other Investment Styles?</h2><ul><li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li><li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li><li>Find companies with promising cash flow potential yet trading below their fair value.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation. We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if Q2 Holdings might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

KRYS

PLTR

AVPT

<p>The U.S. market has seen a 29% increase over the past year, with earnings expected to grow by 16% annually. Key high-growth tech stocks include Marker Therapeutics, Palantir Technologies, and Krystal Biotech, showcasing significant revenue and earnings growth. AvePoint, Krystal Biotech, and Q2 Holdings are highlighted for their innovative approaches and strong financial performance, with each company adapting to market demands and focusing on AI and digital solutions. The overall trend indicates a robust environment for tech investments in the U.S.</p>

- The U.S. market has remained flat over the last week but shows a 29% increase year-over-year, with earnings expected to grow 16% annually.  
- Key high-growth tech companies include AvePoint, Krystal Biotech, and Q2 Holdings, each demonstrating significant revenue and earnings growth, alongside strategic innovations in their fields.  
- The article emphasizes the importance of identifying companies that adapt to positive market conditions, highlighting the potential for future returns in the tech sector.

High Growth Tech Stocks To Watch In The US April 2026